Programmed Cell Death-1/Programmed Death-Ligand 1 Blockade Improves Survival of Animals with Sepsis: A Systematic Review and Meta-Analysis

Programmed Cell Death-1/Programmed Death-Ligand 1 Blockade Improves Survival of Animals with Sepsis: A Systematic Review and Meta-Analysis

Object. To investigate effects of programmed cell death-1 (PD-1) related blockade in sepsis animals. Methods. Two reviewers independently searched electronic databases including PubMed, EMBASE, and the Cochrane Library up to February 2017. Strict literature retrieval and data extraction were perform...

Full description

Bibliographic Details
Main Authors:	Qiang Zhang, Zhijiang Qi, Bo-Liu, Chun-Sheng Li
Format:	Article
Language:	English
Published:	Hindawi Limited 2018-01-01
Series:	BioMed Research International
Online Access:	http://dx.doi.org/10.1155/2018/1969474

Similar Items

Programmed Cell Death-1/Programmed Death-ligand 1 Pathway: A New Target for Sepsis
by: Qiang Liu, et al.
Published: (2017-01-01)

Programmed death-1 and programmed death ligand-1 blockade for advanced urothelial carcinoma
by: Jhe-Cyuan Guo, et al.
Published: (2019-01-01)

Soluble programmed cell death protein-1 and programmed cell death ligand-1 in sepsis
by: Debasree Banerjee, et al.
Published: (2018-06-01)

Programmed death ligand-1/programmed death-1 inhibition therapy and programmed death ligand-1 expression in urothelial bladder carcinoma
by: Wei-Bo Yu, et al.
Published: (2019-09-01)

Modulation of Gut Microbiota: A Novel Paradigm of Enhancing the Efficacy of Programmed Death-1 and Programmed Death Ligand-1 Blockade Therapy
by: Yiming Wang, et al.
Published: (2018-03-01)

Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma
by: Run-Cong Nie, et al.
Published: (2020-06-01)

Research Progress Concerning Dual Blockade of Lymphocyte-Activation Gene 3 and Programmed Death-1/Programmed Death-1 Ligand-1 Blockade in Cancer Immunotherapy: Preclinical and Clinical Evidence of This Potentially More Effective Immunotherapy Strategy
by: Yihang Qi, et al.
Published: (2021-01-01)

Programmed Death-1/Programmed Death-Ligand 1-Axis Blockade in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Stratified by Human Papillomavirus Status: A Systematic Review and Meta-Analysis
by: Yimin Xu, et al.
Published: (2021-04-01)

The Efficacy and Safety of Programmed Death-1 and Programmed Death Ligand 1 Inhibitors for the Treatment of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
by: Shukang He, et al.
Published: (2021-03-01)

Widespread Hypertrophic Lichen Planus following Programmed Cell Death Ligand 1 Blockade
by: Caitlyn N. Myrdal, et al.
Published: (2020-06-01)

Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLC
by: Biagio Ricciuti, MD, et al.
Published: (2020-11-01)

Efficacy and safety of programmed cell death-1/programmed cell death ligand-1 inhibitors in advanced urothelial malignancy: A systematic review and meta-analysis
by: Smita Pattanaik, et al.
Published: (2019-01-01)

Biomarkers for immune checkpoint therapy targeting programmed death 1 and programmed death ligand 1
by: Jingjing Fan, et al.
Published: (2020-10-01)

Inhibition of Programmed Death Receptor-1/Programmed Death Ligand-1 Interactions by Ginsenoside Metabolites
by: Nam-Hui Yim, et al.
Published: (2020-04-01)

Programmed cell death-1 and programmed cell death ligand-1 antibodies-induced dysthyroidism
by: Jaafar Jaafar, et al.
Published: (2018-05-01)

Expression of programmed death-ligand 1 and programmed death-1 in patients with extramammary paget's disease
by: Hiroyuki Goto, et al.
Published: (2021-01-01)

Efficacy and Feasibility of Programmed Death-1/Programmed Death Ligand-1 Blockade Therapy in Non-Small Cell Lung Cancer Patients With High Antinuclear Antibody Titers
by: Atsuto Mouri, et al.
Published: (2021-03-01)

Predictive Values of Programmed Cell Death-Ligand 1 Expression for Prognosis, Clinicopathological Factors, and Response to Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Inhibitors in Patients With Gynecological Cancers: A Meta-Analysis
by: Chen Zhang, et al.
Published: (2021-02-01)

Breast cancer immunology and immunotherapy: targeting the programmed cell death protein-1/programmed cell death protein ligand-1
by: Jing Zhao, et al.
Published: (2020-04-01)

644 Ocular adverse events associated with programmed death-1 and programmed death ligand-1 immunotherapy
by: James Murray, et al.
Published: (2020-11-01)

Antagonizing programmed death-1 and programmed death ligand-1 as a therapeutic approach for gastric cancer
by: Xiaojun Liu, et al.
Published: (2016-11-01)

Regulation of Neuroinflammation through Programmed Death-1/Programmed Death Ligand Signaling in Neurological Disorders
by: Shangfeng eZhao, et al.
Published: (2014-09-01)

Programmed cell death protein 1 and programmed death ligand 1 expression in neuroendocrine carcinomas of the urinary bladder
by: Arbil Acikalin, et al.
Published: (2021-02-01)

Programmed cell death-1 blockade in recurrent disseminated Ewing sarcoma
by: Georgia J. B. McCaughan, et al.
Published: (2016-06-01)

A Novel Role for Programmed Cell Death Receptor Ligand-1 in Sepsis-Induced Intestinal Dysfunction
by: Youping Wu, et al.
Published: (2016-10-01)

Status of programmed death-ligand 1 expression in sarcomas
by: Hyung Kyu Park, et al.
Published: (2018-11-01)

Use of Programmed Death Receptor-1 and/or Programmed Death Ligand 1 Inhibitors for the Treatment of Brain Metastasis of Lung Cancer
by: Wang S, et al.
Published: (2020-01-01)

Programmed Cell Death Protein-1 Inhibitors Versus Programmed Death-Ligand 1 Inhibitors in Addition to Chemotherapy for the First-Line Treatment of Advanced NSCLC: A Systematic Review and Meta-Analysis
by: Alessandro Di Federico, MD, et al.
Published: (2021-09-01)

Fatal adverse events associated with programmed cell death protein 1 or programmed cell death-ligand 1 monotherapy in cancer
by: Bin Zhao, et al.
Published: (2020-02-01)

Review of Cancer Immunotherapy: Application of Chimeric Antigen Receptor T Cells and Programmed Death 1/Programmed Death-ligand 1 Antibodies
by: Tengfei Zhang, et al.
Published: (2015-01-01)

Fatal Adverse Events Associated With Programmed Cell Death Ligand 1 Inhibitors: A Systematic Review and Meta-Analysis
by: Xuewen Wang, et al.
Published: (2020-01-01)

Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis
by: Xiaoying Sun, et al.
Published: (2019-06-01)

Recent Findings in the Regulation of Programmed Death Ligand 1 Expression
by: Xiangfeng Shen, et al.
Published: (2019-06-01)

The Prognostic Value of Circulating Soluble Programmed Death Ligand-1 in Cancers: A Meta-Analysis
by: Pei Huang, et al.
Published: (2021-02-01)

Prognostic and Clinicopathological Value of Programmed Death Ligand-1 in Breast Cancer: A Meta-Analysis.
by: Yawen Guo, et al.
Published: (2016-01-01)

Comprehensive insights into the effects and regulatory mechanisms of immune cells expressing programmed death-1/programmed death ligand 1 in solid tumors
by: Min Liu, et al.
Published: (2020-08-01)

IL-1β but not programmed death-1 and programmed death-ligand pathway is critical for the human Th17 response to M. tuberculosis
by: Emmanuel Stephen-Victor, et al.
Published: (2016-11-01)

Elevated Expression of Programmed Death-1 and Programmed Death Ligand-1 Negatively Regulates Immune Response against Cervical Cancer Cells
by: Zhifang Chen, et al.
Published: (2016-01-01)

Current Landscape of Immunotherapy Trials Involving the Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Axis in Intrathoracic Tumors
by: Samuel A. Kareff, MD, MPH, et al.
Published: (2021-04-01)

Corrigendum: Breast cancer immunology and immunotherapy: targeting the programmed cell death protein-1/programmed cell death protein ligand-1
Published: (2021-03-01)